Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.

Mann JFE, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P, Seufert J, Tadayon S, Vilsbøll T

The lancet. Diabetes & endocrinology21 Sept 2020Cited by 127 (Europe PMC)

PMID32971040DOI10.1016/s2213-8587(20)30313-2PepBankPUB-32971040

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. 19 results from people.

01HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes in SUSTAIN 1-7, kidney adverse events were balanced between semaglutide and comparator groups.
In plain wordsIn adults with type 2 diabetes, kidney side effects were similar between semaglutide and comparator groups.
Peptide
Semaglutide
Outcome
No significant changeKidney adverse events
Study
n = 8,416
Comparator
Comparators (active treatments or placebo)
Outcome group
Adverse events · Kidney and urinary
Studied dose
0.5 mg and 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Kidney adverse events were balanced between treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104019
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-5 and 7, semaglutide 0.5 mg lowered eGFR more than placebo from baseline to week 12.
In plain wordsIn adults with type 2 diabetes, eGFR fell slightly more with semaglutide 0.5 mg than with placebo over 12 weeks.
Peptide
Semaglutide
Outcome
DecreaseeGFR change baseline to week 12, SUSTAIN 1-5 and 7, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
−2.15 mL/min per 1.73 m2
0.5 mg vs placebo, week 12
Source sentences
Summary
In SUSTAIN 1-5 and SUSTAIN 7, eGFR decreased from baseline to week 12 with all active treatments; estimated treatment differences (ETDs) versus placebo were -2·15 (95% CI -3·47 to -0·83) mL/min per 1·73 m² with semaglutide 0·5 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104001
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-5 and 7, semaglutide 1.0 mg lowered eGFR more than placebo from baseline to week 12.
In plain wordsIn adults with type 2 diabetes, eGFR fell slightly more with semaglutide 1.0 mg than with placebo over 12 weeks.
Peptide
Semaglutide
Outcome
DecreaseeGFR change baseline to week 12, SUSTAIN 1-5 and 7, 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
−3 mL/min per 1.73 m2
1.0 mg vs placebo, week 12
Source sentences
Summary
and -3·00 (-4·31 to -1·68) mL/min per 1·73 m² with semaglutide 1·0 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104002
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-5 and 7, eGFR plateaued after week 12.
In plain wordsIn adults with type 2 diabetes, the eGFR drop levelled off after week 12 on semaglutide.
Peptide
Semaglutide
Outcome
No significant changeeGFR after week 12, SUSTAIN 1-5 and 7
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg and 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
after week 12, eGFR plateaued.
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104003
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-5 and 7, the eGFR decline to end of treatment was greater with semaglutide 0.5 mg than with placebo.
In plain wordsIn adults with type 2 diabetes, eGFR declined more with semaglutide 0.5 mg than with placebo over the trial.
Peptide
Semaglutide
Outcome
DecreaseeGFR decline baseline to end of treatment, SUSTAIN 1-5 and 7, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
−1.58 mL/min per 1.73 m2
0.5 mg vs placebo, end of treatment
Source sentences
Summary
In SUSTAIN 1-5 and SUSTAIN 7, from baseline to end of treatment the decline in eGFR was greater with semaglutide than with placebo (ETD -1·58 [95% CI -2·92 to -0·25] mL/min per 1·73 m² with semaglutide 0·5 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104004
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-5 and 7, the eGFR decline to end of treatment was greater with semaglutide 1.0 mg than with placebo.
In plain wordsIn adults with type 2 diabetes, eGFR declined more with semaglutide 1.0 mg than with placebo over the trial.
Peptide
Semaglutide
Outcome
DecreaseeGFR decline baseline to end of treatment, SUSTAIN 1-5 and 7, 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
−2.02 mL/min per 1.73 m2
1.0 mg vs placebo, end of treatment
Source sentences
Summary
and -2·02 [-3·35 to -0·68] mL/min per 1·73 m² with semaglutide 1·0 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104005
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, the eGFR decline to week 16 was greater with semaglutide 0.5 mg than with placebo.
In plain wordsIn adults with type 2 diabetes in SUSTAIN 6, eGFR declined more with semaglutide 0.5 mg than with placebo in the first 16 weeks.
Peptide
Semaglutide
Outcome
DecreaseeGFR decline baseline to week 16, SUSTAIN 6, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
−1.29 mL/min per 1.73 m2
0.5 mg vs placebo, baseline to week 16
Source sentences
Summary
In SUSTAIN 6, the decline in eGFR was greater with semaglutide than with placebo from baseline to week 16 (ETD -1·29 [95% CI -2·07 to -0·51] mL/min per 1·73 m² with semaglutide 0·5 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104006
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, the eGFR decline to week 16 was greater with semaglutide 1.0 mg than with placebo.
In plain wordsIn adults with type 2 diabetes in SUSTAIN 6, eGFR declined more with semaglutide 1.0 mg than with placebo in the first 16 weeks.
Peptide
Semaglutide
Outcome
DecreaseeGFR decline baseline to week 16, SUSTAIN 6, 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
−1.56 mL/min per 1.73 m2
1.0 mg vs placebo, baseline to week 16
Source sentences
Summary
and -1·56 [-2·33 to -0·78] mL/min per 1·73 m² with semaglutide 1·0 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104007
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, from week 16 to week 104 the eGFR decline was not greater with semaglutide 0.5 mg than with placebo; the estimated difference was positive.
In plain wordsIn adults with type 2 diabetes in SUSTAIN 6, eGFR did not fall more with semaglutide 0.5 mg than with placebo after week 16.
Peptide
Semaglutide
Outcome
IncreaseeGFR change week 16 to week 104, SUSTAIN 6, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg · subcutaneous · 104 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
1.29 mL/min per 1.73 m2
0.5 mg vs placebo, week 16 to 104
Source sentences
Summary
but not from week 16 to week 104 (1·29 [0·30 to 2·28] mL/min per 1·73 m² with semaglutide 0·5 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104008
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, from week 16 to week 104 the eGFR decline was not greater with semaglutide 1.0 mg than with placebo; the estimated difference was positive.
In plain wordsIn adults with type 2 diabetes in SUSTAIN 6, eGFR did not fall more with semaglutide 1.0 mg than with placebo after week 16.
Peptide
Semaglutide
Outcome
IncreaseeGFR change week 16 to week 104, SUSTAIN 6, 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · subcutaneous · 104 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
2.44 mL/min per 1.73 m2
1.0 mg vs placebo, week 16 to 104
Source sentences
Summary
and 2·44 [1·45 to 3·44] mL/min per 1·73 m² with semaglutide 1·0 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104009
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, the overall eGFR decline to week 104 was similar between semaglutide 0.5 mg and placebo.
In plain wordsIn adults with type 2 diabetes in SUSTAIN 6, the overall eGFR decline over 104 weeks was similar with semaglutide 0.5 mg and placebo.
Peptide
Semaglutide
Outcome
No significant changeeGFR decline baseline to week 104, SUSTAIN 6, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg · subcutaneous · 104 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
0.07 mL/min per 1.73 m2
0.5 mg vs placebo, week 104
Source sentences
Summary
Overall (ie, from baseline to week 104), the eGFR decline in SUSTAIN 6 was similar between semaglutide and placebo (ETD 0·07 [95% CI -0·92 to 1·07] mL/min per 1·73 m² with semaglutide 0·5 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104010
12HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, the overall eGFR decline to week 104 was similar between semaglutide 1.0 mg and placebo.
In plain wordsIn adults with type 2 diabetes in SUSTAIN 6, the overall eGFR decline over 104 weeks was similar with semaglutide 1.0 mg and placebo.
Peptide
Semaglutide
Outcome
No significant changeeGFR decline baseline to week 104, SUSTAIN 6, 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · subcutaneous · 104 weeksAs given in this study (human).
Measurements
Estimated treatment difference in eGFR
0.97 mL/min per 1.73 m2
1.0 mg vs placebo, week 104
Source sentences
Summary
and 0·97 [-0·03 to 1·97] mL/min per 1·73 m² with semaglutide 1·0 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104011
13HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-7, eGFR did not differ between semaglutide and placebo overall, although it initially declined in patients with normal kidney function.
In plain wordsIn adults with type 2 diabetes, eGFR did not differ between semaglutide and placebo by the end of treatment.
Peptide
Semaglutide
Outcome
No significant changeeGFR at end of treatment in SUSTAIN 1-7 by kidney function
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg and 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
In SUSTAIN 1-7, eGFR initially declined in patients with normal kidney function (and in those with mild kidney impairment with semaglutide 1·0 mg in SUSTAIN 6), but overall (ie, by week 30 for SUSTAIN 1-5 and SUSTAIN 7, and week 104 for SUSTAIN 6), eGFR did not differ between semaglutide and placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104012
14HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-5, semaglutide 0.5 mg reduced UACR more than placebo at end of treatment.
In plain wordsIn adults with type 2 diabetes, semaglutide 0.5 mg lowered urine albumin more than placebo.
Peptide
Semaglutide
Outcome
DecreaseUACR ratio at end of treatment, SUSTAIN 1-5, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg · subcutaneousAs given in this study (human).
Measurements
Estimated treatment ratio of UACR
0.74 ratio
0.5 mg vs placebo
Source sentences
Summary
greater reductions in UACR were observed with semaglutide versus placebo (estimated treatment ratios 0·74 [95% CI 0·64 to 0·85] for semaglutide 0·5 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104013
15HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-5, semaglutide 1.0 mg reduced UACR more than placebo at end of treatment.
In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg lowered urine albumin more than placebo.
Peptide
Semaglutide
Outcome
DecreaseUACR ratio at end of treatment, SUSTAIN 1-5, 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · subcutaneousAs given in this study (human).
Measurements
Estimated treatment ratio of UACR
0.68 ratio
1.0 mg vs placebo
Source sentences
Summary
greater reductions in UACR were observed with semaglutide versus placebo (estimated treatment ratios 0·74 [95% CI 0·64 to 0·85] for semaglutide 0·5 mg and 0·68 [0·59 to 0·78] for semaglutide 1·0 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104014
16HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, semaglutide 0.5 mg reduced UACR more than placebo at week 104.
In plain wordsIn adults with type 2 diabetes, semaglutide 0.5 mg lowered urine albumin more than placebo at week 104.
Peptide
Semaglutide
Outcome
DecreaseUACR ratio at week 104, SUSTAIN 6, 0.5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg · subcutaneous · 104 weeksAs given in this study (human).
Measurements
Estimated treatment ratio of UACR
0.75 ratio
0.5 mg vs placebo
Source sentences
Summary
at week 104, greater reductions in UACR were observed with semaglutide versus placebo (estimated treatment ratios 0·75 [95% CI 0·66 to 0·85] for semaglutide 0·5 mg
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104015
17HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 6, semaglutide 1.0 mg reduced UACR more than placebo at week 104.
In plain wordsIn adults with type 2 diabetes, semaglutide 1.0 mg lowered urine albumin more than placebo at week 104.
Peptide
Semaglutide
Outcome
DecreaseUACR ratio at week 104, SUSTAIN 6, 1.0 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.0 mg · subcutaneous · 104 weeksAs given in this study (human).
Measurements
Estimated treatment ratio of UACR
0.66 ratio
1.0 mg vs placebo
Source sentences
Summary
at week 104, greater reductions in UACR were observed with semaglutide versus placebo (estimated treatment ratios 0·75 [95% CI 0·66 to 0·85] for semaglutide 0·5 mg and 0·66 [0·58 to 0·75] for semaglutide 1·0 mg).
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104016
18HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-6, UACR decreased in patients with pre-existing microalbuminuria or macroalbuminuria at baseline.
In plain wordsIn adults with type 2 diabetes, urine albumin fell in patients who already had raised urine albumin when starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseUACR in patients with micro- or macroalbuminuria at baseline
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg and 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
In SUSTAIN 1-6, UACR decreased in patients with pre-existing microalbuminuria or macroalbuminuria at baseline
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104017
19HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in SUSTAIN 1-6, UACR did not change or increased in patients with normoalbuminuria at baseline.
In plain wordsIn adults with type 2 diabetes, urine albumin did not change or rose in patients with normal urine albumin at the start.
Peptide
Semaglutide
Outcome
MixedUACR in patients with normoalbuminuria at baseline
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.5 mg and 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
it did not change or increased in those with normoalbuminuria at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
We did a post-hoc analysis of 8416 patients with type 2 diabetes enrolled in the SUSTAIN 1-5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial
Report a problemFND-3297104018

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.